Studies have investigated the potential of PSMA PET/CT for the detection of intermediate- to high-risk intraprostatic tumour lesions [17–19], while the utility of detecting PSA grey zone PCa and csPCa in the pre-biopsy setting is uncertain. This evidence concerns the gene FOLH1 and posterior cortical atrophy.